Jack Weinstein serves as Chief Financial Officer and Treasurer. He brings over 40 years of executive management expertise in investment banking and consulting in the biopharmaceutical and life sciences industries. Jack has extensive experience in corporate finance, business development as well as FDA regulatory and intellectual property strategies.

Anthony serves as Senior Vice President and Head of U.S. Commercial Operations. He is a highly experienced pharmaceutical executive with a successful track record in launch execution, strategic planning and marketing across a variety of indications.

Paolo Galfetti is President of Relief Europe. He has over 20 years of management experience in the pharmaceutical sector, including in the areas of business development and licensing, operational strategic management, clinical research, and pharmaceutical discovery and development. 

Jeremy Meinen, Vice President Finance & Administration and Chief Accounting Officer, serves as principal finance and accounting officer. Prior to joining Relief, Jeremy provided financial consulting and controlling services to companies in various industries. Jeremy is a Swiss certified public accountant.

Marco Marotta serves as Chief Business Officer. He brings deep, international expertise in operations, sales and business development within the pharmaceutical sector.

Dr. Varawalla serves as Chief Medical Officer. She brings over 30 years of expertise in clinical trials, regulatory matters and medical affairs, with a track record of leading numerous international teams and clinical development programs for the global adoption of new pharmaceuticals and medical devices.

Dr. Bevec serves as Chief Scientific Officer. He brings over 35 years of broad scientific knowledge and extensive research and development capabilities with experience at numerous academic and pharmaceutical companies including drug development and discovery, repositioning and repurposing for rare and respiratory diseases. 

Drew serves as Executive Director and Head of U.S. Marketing. She is proven leader, with a successful track record of launching numerous products in the rare disease space, and has deep expertise in digital technology, strategic planning and team building.

Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. serves as Manufacturing and Supply Chain Consultant to Relief. He is a highly experienced pharmaceutical consultant with more than 25 years of expertise in the areas of regulatory affairs, life cycle management, pharmaceutical development and Good Manufacturing Practice (GMP).

J. Paul Waymack, M.D., Sc.D. serves as Development and Regulatory Consultant for Relief. He has an extensive track record in the pharmaceutical drug development arena and currently serves as President of Waymack Consulting, which provides expert services to healthcare companies.

Raghuram (Ram) Selvaraju, Ph.D., MBA, is a Managing Director and Senior Healthcare Analyst in the Equity Research Division of H.C. Wainwright & Co., a New York-based full-service investment bank heavily focused on the healthcare sector. He has over 15 years of experience on Wall Street and previously was a pharmaceutical researcher at Serono in Switzerland. He holds Ph.D. and M.S. degrees from the University of Geneva and an M.B.A. from Cornell University.

Paolo Galfetti is President of Relief Europe. He has over 20 years of management experience in the pharmaceutical sector, including in the areas of business development and licensing, operational strategic management, clinical research, and pharmaceutical discovery and development.

Patrice Jean is the Chair of the Life Sciences Practice at Hughes Hubbard & Reed, an international law firm based in New York City. She has over a decade of experience counselling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law, including asserting and defending patent rights underlying core technologies and innovations.

Tom Plitz recently served as Chief Executive Officer of Chord Therapeutics SA, a privately held biopharmaceutical firm based in Geneva, Switzerland, which was acquired by Merck KGaA in January 2022. He has more than two decades of R&D experience from senior management positions in the pharmaceutical industry.

Michelle Lock is the Chief Operating Officer of Covis Pharma Group, a global specialty pharmaceutical company based in Zug, Switzerland. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience.